Close Menu

NEW YORK (360Dx) – Mologic and PATH said today that they have entered an agreement to advance a new rapid diagnostic test (RDT) to support treating and eliminating Plasmodium vivax malaria.

PATH, an international nonprofit with a focus on improving health, especially among women and children, is supporting Mologic in commercializing the RDT and obtaining regulatory approvals.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.